Topical cyclosporine can handle more than dry-eye disease

June 15, 2004

Article

Any T-cell-mediated disease benefits from therapy without affecting other inflammatory pathways

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Subscribe Now!

Recent Videos

Rajeev Sivasankaran, PhD, vice president of neuroscience at Voyager Therapeutics

Sven Moller-Tank, PhD, a senior director at Regeneron

Alexey Danilov, MD, PhD, the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, codirector of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California

About Us

Editorial

Terms and Conditions

Do Not Sell My Information

Privacy

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Topical cyclosporine can handle more than dry-eye disease

Newsletter